Literature DB >> 16401381

Selection of optimal therapy for chronic stable angina.

Udho Thadani1.   

Abstract

Patients with chronic stable angina (CSA) seek a medical opinion for relief of their symptoms and because of fear of having a heart attack. The underlying lesion responsible for CSA is often a severe narrowing of one or more coronary arteries. In addition, the coronary arteries of patients with CSA contain many more nonobstructive lesions, which progress at variable rates, and are prone to rupture and may manifest as acute coronary syndromes (myocardial infarction , unstable angina , or sudden ischemic death). Most patients with CSA can be managed with medical treatment. For angina relief, optimum doses of one of the antianginal drugs (beta blockers , long-acting organic nitrates, or calcium channel blockers ) should be used. If the patient remains symptomatic, combination treatment of BBs plus nitrates or BBs plus dihydropyridine CCBs, or nondihydropyridine CCBs plus nitrates should be tried. Triple therapy has not been shown to be more effective than treatment with two agents. To reduce the incidence of MI, UA, and sudden ischemic death, treatment strategies should include smoking cessation, daily aspirin, daily exercise, and pharmacologic therapy for dyslipidemias, and for elevated blood pressure. Patients who remain symptomatic despite medical therapy and those not willing to take or unable to tolerate antianginal drugs should be considered for percutaneous or surgical coronary revascularization. Patients who do not respond to medical therapy and are not candidates for a revascularization procedure may be considered for additional treatment with trimetazidine or nicorandil (these drugs are not available in the United States or approved by the US Food and Drug Administration, but are available in some other countries). Ranolazine also looks promising but is not yet available for clinical use. As a last resort, enhanced external counterpulsation, spinal cord stimulation, sympathectomy, or direct transmyocardial revascularization should be considered for symptom relief.

Entities:  

Year:  2006        PMID: 16401381     DOI: 10.1007/s11936-006-0023-9

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  51 in total

1.  Selective L-type, T-type, and nonspecific calcium-channel blockers for stable angina pectoris.

Authors:  Udho Thadani
Journal:  Am Heart J       Date:  2002-07       Impact factor: 4.749

2.  Recurrent and refractory angina following revascularization procedures in patients with stable angina pectoris.

Authors:  Udho Thadani
Journal:  Coron Artery Dis       Date:  2004-05       Impact factor: 1.439

Review 3.  Combined use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina. Rationale, efficacy, and adverse effects.

Authors:  W E Strauss; A F Parisi
Journal:  Ann Intern Med       Date:  1988-10-01       Impact factor: 25.391

4.  Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Studies in Angina Research (CESAR) Investigators.

Authors:  C J Knight; K M Fox
Journal:  Am J Cardiol       Date:  1998-01-15       Impact factor: 2.778

5.  Trimetazidine in Angina Combination Therapy--the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study.

Authors:  E I Chazov; V K Lepakchin; E A Zharova; S B Fitilev; A M Levin; E G Rumiantzeva; T B Fitileva
Journal:  Am J Ther       Date:  2005 Jan-Feb       Impact factor: 2.688

6.  Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris: the ESBY study.

Authors:  C Mannheimer; T Eliasson; L E Augustinsson; C Blomstrand; H Emanuelsson; S Larsson; H Norrsell; A Hjalmarsson
Journal:  Circulation       Date:  1998-03-31       Impact factor: 29.690

Review 7.  The prognosis in stable and unstable angina.

Authors:  T C Hilton; B R Chaitman
Journal:  Cardiol Clin       Date:  1991-02       Impact factor: 2.213

8.  Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.

Authors: 
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

Review 9.  Refractory angina pectoris: mechanism and therapeutic options.

Authors:  Michael C Kim; Annapoorna Kini; Samin K Sharma
Journal:  J Am Coll Cardiol       Date:  2002-03-20       Impact factor: 24.094

10.  Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease.

Authors:  D B Mark; L Shaw; F E Harrell; M A Hlatky; K L Lee; J R Bengtson; C B McCants; R M Califf; D B Pryor
Journal:  N Engl J Med       Date:  1991-09-19       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.